First-ever in-utero stem cell therapy for fetal spina bifida repair is safe

UC Davis Health has announced a landmark achievement in fetal medicine with the successful completion of Phase 1 of the CuRe Trial. This pioneering study marks the first time an in-utero stem cell therapy has been combined with fetal surgery to treat spina bifida, a severe birth defect. The research focused on assessing the safety of this novel approach, showing promising results that could revolutionize care for affected children.

• The CuRe Trial combines standard fetal surgery with a patch of human placenta-derived stem cells applied directly over the exposed spinal cord of the fetus.
• Spina bifida, or myelomeningocele, results from spinal tissue failing to fuse during early pregnancy, leading to various lifelong disabilities.
• Phase 1 of the trial specifically evaluated the safety of introducing stem cells, reporting no infections, spinal fluid leaks, or abnormal tissue growth.
• All six surgeries performed were successful, with the stem cell patch correctly placed and wounds healed, and MRI scans showed reversal of hindbrain herniation in all infants.
• Crucially, no babies required shunting for hydrocephalus before hospital discharge, indicating improved neurological outcomes.
• This therapy is the first in-utero stem cell treatment for spina bifida globally, aiming to enhance regenerative healing beyond what traditional fetal surgery alone offers.
• The study is funded by grants from the California Institute for Regenerative Medicine (CIRM) and Shriners Children's, and Phase 1/2a is now enrolling up to 35 patients.

This breakthrough represents a major stride towards a new era of fetal therapy, moving beyond mere repair to active healing and protection of the developing spinal cord. The potential for improved mobility and quality of life for children with spina bifida offers profound hope and signifies the exciting future of cell and gene therapy before birth.